scholarly journals Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose

Diabetologia ◽  
1999 ◽  
Vol 42 (2) ◽  
pp. 177-180 ◽  
Author(s):  
J. B. Ruige ◽  
J. M. Dekker ◽  
G. Nijpels ◽  
C. Popp-Snijders ◽  
C. D. A. Stehouwer ◽  
...  
1970 ◽  
Vol 65 (1) ◽  
pp. 155-169 ◽  
Author(s):  
W. W. Shreeve ◽  
E. Cerasi ◽  
R. Luft

ABSTRACT In 4 studies on 3 acromegalic patients, who had normal iv glucose tolerance and high insulin response to infused glucose (Al), the oxidation to 14CO2 of [2-14C] pyruvate (injected intravenously in trace amount after overnight fast) was not different from that in 9 studies of 9 nonacromegalic »high insulin responders« (Ni). In 4 studies on 3 other acromegalic patients, who had low glucose tolerance and less insulin response to glucose (A2), the formation of 14CO2 was reduced to ½–⅔ that of Al or N1 and was about proportionate to the reduction in glucose tolerance. In A2 the 14CO2 formation was slightly lower than the mean for 10 studies with 7 non-acromegalic subjects, who were »low insulin responders« with normal or low glucose tolerance (N2). Among non-acromegalics expiration of 14CO2 was significantly lower in N2 than in N1. Among 4 non-acromegalic subjects treated with human growth hormone for 3–4 days one had a marked reduction in pyruvate oxidation, while all had a decrease in glucose tolerance. Analysis of 14C in blood glucose at 60 minutes after injection of [2-14C]pyruvate suggested that slightly more total 14C-glucose was present in A2 than N1 without any differences between A2 and N2 or N1 and N2. Two out of 4 studies in A1 showed lower than normal amounts of 14Cglucose. No change in 14C-glucose occurred after administration of HGH. The findings suggest that impairment of pyruvate oxidation accompanies a lowered glucose tolerance in acromegalics with a diabetic tendency. Changes in gluconeogenesis from pyruvate appear to be minimal.


1980 ◽  
Vol 17 (1) ◽  
pp. 1-7 ◽  
Author(s):  
John P. Monson ◽  
Leslie J. Borthwick ◽  
Gerassimos S. Spathis ◽  
Stephen R. Bloom

Diabetes Care ◽  
2000 ◽  
Vol 23 (5) ◽  
pp. 710-712 ◽  
Author(s):  
Y. Tanaka ◽  
Y. Atsumi ◽  
K. Matsuoka ◽  
T. Onuma ◽  
R. Kawamori

1997 ◽  
pp. 127-131 ◽  
Author(s):  
B Ahren ◽  
H Larsson ◽  
JJ Holst

OBJECTIVE: The gastrointestinal hormones, gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), are both released from the gut after oral glucose ingestion and stimulate insulin secretion. This study examined the release of these hormones in subjects with impaired glucose tolerance (IGT), which precedes the development of non-insulin-dependent diabetes. DESIGN AND METHODS: Six postmenopausal women with IGT, aged 59 years, underwent a 75 g oral glucose tolerance test and plasma levels of GIP and GLP-1 were determined regularly during the following 2 h. The results were compared with those in seven age- and weight-matched women with normal glucose tolerance (NGT). RESULTS: Basal plasma levels of GIP and GLP-1 were not different between the groups. In response to the oral glucose ingestion, plasma levels of both GIP and GLP-1 increased in both groups. The plasma GIP increase after glucose ingestion was, however, reduced in women with IGT. Thus, the GIP response as determined as the area under the curve for the 60 min after oral glucose was 34.8 +/- 3.2 pmol/l per min in women with IGT versus 56.4 +/- 7.8 pmol/l per min in those with NGT (P = 0.021). In contrast, the GLP-1 response to oral glucose was not different between the groups. By definition, the glucose response to oral glucose was markedly increased in women with IGT, and the insulin response during the second hour after glucose ingestion was exaggerated. CONCLUSIONS: The GIP response to oral glucose is impaired in postmenopausal women with IGT, whereas the plasma GLP-1 response is not affected.


1983 ◽  
Vol 104 (1) ◽  
pp. 85-90 ◽  
Author(s):  
X. Jeanrenaud ◽  
E. Maeder ◽  
E. Del Pozo ◽  
J. P. Felber

Abstract. The purpose of the present work was to study the effect of a methionine-enkephalin analogue (FK 33-824) on glucose tolerance in man. Groups of 5 to 8 normal subjects were given a 0.5 mg im injection of the drug or placebo just before a 100 g oral glucose load or a 0.5 g/kg iv glucose load. In the enkephalin analogue treated subjects, diminished insulin response to glucose was observed following the oral glucose load, with insulin values significantly lower than in the controls from time 10 to 90 min, but no corresponding change in the glucose curve. This effect was not observed when glucose was given iv in another group of 5 subjects in whom the significant blunting of the insulin response was accompanied by a significant decrease in glucose tolerance. These observations demonstrate that in man, enkephalin produces a decrease in insulin secretion in response to both oral and iv glucose loads. The absence of any marked impairment in glucose tolerance in the oral test in spite of the decreased insulin response suggests that enkephalin might have an additional effect in delaying glucose absorption.


Diabetologia ◽  
1995 ◽  
Vol 38 (2) ◽  
pp. 187-192 ◽  
Author(s):  
D. K. Nagi ◽  
W. C. Knowler ◽  
M. A. Charles ◽  
Q. Z. Liu ◽  
R. L. Hanson ◽  
...  

1969 ◽  
Vol 62 (2) ◽  
pp. 242-250 ◽  
Author(s):  
U. Larsson-Cohn ◽  
B. Tengström ◽  
L. Wide

ABSTRACT Intravenous glucose tolerance tests and insulin determinations were performed on 37 women at different stages of the menstrual cycle and after one, three and twelve months of daily continuous treatment with 0.5 mg of norethindrone or 0.5 mg of chlormadinone acetate. The fasting blood glucose concentration, the k-values (percentage disappearance rate of glucose per minute) and the insulin response to glucose administration were compared. No statistically significant differences were found between the values obtained on two occasions before treatment, and during treatment.


Diabetes ◽  
1968 ◽  
Vol 17 (1) ◽  
pp. 17-26 ◽  
Author(s):  
J. S. Soeldner ◽  
R. E. Gleason ◽  
R. F. Williams ◽  
M. J. Garcia ◽  
D. M. Beardwood ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document